InvestSMART

Imugene Limited (ASX: IMU) - ETF Exposure

Current share price for IMU : $0.070 0.001 (1.41%)+

Imugene Limited (IMU) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. The Company's unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

IMU General Information +

ASX Code IMU
Website http://www.imugene.com
Industry/Sector Biotechnology
Market Cap ($M) 36
IMU Share Price $0.070
Day High $0.073
Day Low $0.070
Last Close $0.071
IMU Share Price Movement $0.00 ( 1.41% )
Prices as at 16:40, 28 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Imugene Limited (IMU) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Imugene Limited (IMU) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Imugene Limited (IMU) price-sensitive announcements

IMU - Quarterly Activities/Appendix 4C Cash Flow Report
Imugene Limited, a clinical-stage cellular therapy company, reported its quarterly activit
Imugene Limited (IMU)
31 Jul 2026 | 9:12 AM
IMU - Third response in concurrent BTKi Cohort of azer-cel Trial
Imugene Limited reported a third patient response in the concurrent BTKi cohort of its aze
Imugene Limited (IMU)
27 Jul 2026 | 9:55 AM
IMU - CEO Resignation
Imugene Limited announced the resignation of Ms. Leslie Chong, who served as the Managing
Imugene Limited (IMU)
27 Jul 2026 | 9:39 AM
IMU - $11.1 Million Placement Completed to Advance azer-cel
Imugene Limited has successfully completed a $11.1 million placement to advance its lead a
Imugene Limited (IMU)
7 Jul 2026 | 9:49 AM

Imugene Limited (IMU) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $36 Corporate Governance Statement and Appendix 4G 28 Aug 2026 5:47PM $0.070 $0.070 fallen by 0%
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $36 Appendix 4E and Annual Report 28 Aug 2026 5:28PM $0.070 $0.070 fallen by 0%
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $36 Notice under section 708A(12C)(e) of the Corporations Act 28 Aug 2026 8:49AM $0.071 $0.070 fallen by 1.41%
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $36 Notice of Initial Substantial Holding from SOL 27 Aug 2026 6:40PM $0.071 $0.070 fallen by 1.41%
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $36 Becoming a substantial holder from PCG 27 Aug 2026 9:33AM $0.071 $0.070 fallen by 1.41%
Imugene Limited (IMU)
ORDINARY FULLY PAID
 Health Care $36 Notification regarding unquoted securities - IMU 26 Aug 2026 5:19PM $0.071 $0.070 fallen by 1.41%

IMU Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2027F C2 -$9.00 -43.80% 0.00 0.00 0.00% 0.0%
2026F C2 -$16.00 -49.30% 0.00 0.00 0.00% 0.0%
2025A -$69.02 -$31.60 -47.50% 0.00 0.00 0.00% 0.0%

IMU Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2026 F 2027 F 2025 A 2026 F 2027 F 2025 A 2026 F 2027 F
CSL Limited (CSL) $83,273M 0.7309 -0.4384 0.0505 10.7722 19.1821 18.2601 2.44% 2.42% 2.50%
Clinuvel Pharmaceuticals Limited (CUV) $463M 0.0287 0.0000 0.0000 12.7855 0.0000 0.0000 0.54% 0.00% 0.00%
Imugene Limited (IMU) $37M -0.4751 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $3,130M -0.4380 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,294M -1.3893 0.0000 -0.9100 0.0000 147.5379 1,640.0000 0.00% 0.00% 0.00%

IMU Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.34 0.00
Market 0.35 13.30 1.17 0.85
Sector 0.64 31.20 2.63 2.65

IMU Directors

Name Position Start Date
Mr Paul Alex Hopper Executive Chairman, Executive Director 31 Oct 2012
Mr Michael John Kotsanis Non-Executive Director 30 Jun 2026
Dr Lesley Russell Non-Executive Director 23 Apr 2019
Dr Charmaine Hilary Gittleson Non-Executive Director 30 Jun 2026
Dr Jakob Dupont Non-Executive Director 7 Sep 2022
Ms Kim Drapkin Non-Executive Director 21 Jun 2023

Imugene Limited (IMU) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
14 May 2026 CHONG, Leslie (Mi Ok) Buy Direct Shares 355,164 $0.103 $36,404.310
14 May 2026 HOPPER, Paul Buy Direct Shares 180,000 $0.104 $18,648.000
11 May 2026 CHONG, Leslie (Mi Ok) Buy Direct Shares 230,285 $0.108 $24,755.638

See all changes in directors' interest & trades for Imugene Limited (IMU) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

IMU Management

Name Position
Darren Keamy Chief Financial Officer
Darren Keamy Chief Financial Officer,Company Secretary
John Byon Chief Medical Officer
Bradley Glover Chief Operating Officer

IMU Calendar of Events

Date Event
27 August 2027 Report (Annual)
27 August 2027 Report (Prelim)
24 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.